Neuronetics, Inc. has announced a public offering of 18,750,000 shares of its common stock, aiming to raise approximately $30 million. This offering is part of the company's strategy to bolster its financial resources and support its growth initiatives in the surgical and medical instruments sector.

The common stock is listed on The Nasdaq Global Market under the ticker symbol “STIM.” As of November 10, 2026, the last reported sale price of the stock was $2.01 per share. The offering is expected to close on November 12, 2026, subject to the satisfaction of certain conditions.

Background

Neuronetics, Inc. is a company focused on developing and commercializing innovative solutions for mental health treatment. The company operates within the Surgical & Medical Instruments & Apparatus industry, classified under the SIC code 3841. Neuronetics is known for its NeuroStar Advanced Therapy System, which provides non-invasive treatment for major depressive disorder and other mental health conditions.

Recent filings indicate that Neuronetics is a smaller reporting company and has opted for reduced public company reporting requirements. The company has been active in the market, with multiple filings in November 2026, including a Form 8-K and a Form 4.

What the Filing Says

According to the recent SEC filing, Neuronetics is offering 18,750,000 shares at a public offering price of $1.60 per share. The company will receive approximately $28.2 million in proceeds before expenses. The underwriters have also been granted an option to purchase an additional 2,812,500 shares at the public offering price, which can be exercised within 30 days of the offering.

“Investing in our common stock involves a high degree of risk,” the filing states, urging potential investors to carefully consider the associated risks.

Impact

This public offering may significantly impact various stakeholders, including current shareholders, potential investors, and competitors within the surgical and medical instruments industry. By raising additional capital, Neuronetics aims to enhance its operational capabilities and expand its market presence, which could lead to increased competition in the sector.

What's Next

The offering is expected to close on or about November 12, 2026, pending the satisfaction of certain conditions. Following this, Neuronetics may provide further updates regarding the use of proceeds and its strategic initiatives.

For more details, refer to the SEC filing (accession number 0001193125-26-457031).